Jump to content
PC Security Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE
  • entries
    274
  • comment
    1
  • views
    304

More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS disorders


The concept of BBB penetration is anticipated to bring about a paradigm shift in modern healthcare. In fact, experts believe that there is an important relationship between the recent pandemic of Coronavirus disease (COVID-19) and cerebrovascular system, presenting commercial opportunities for players engaged in the development of BBB penetrating drugs.

 

To order this 400+ page report, which features 145+ figures and 205+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html

 

The USD 940 million (by 2030) financial opportunity within the BBB market has been analyzed across the following segments:

§  Type of Payment Model Adopted

§  Upfront payments

§  Milestone payments

 

§  Type of Molecule

§  Small Molecules

§  Biologics

 

§  Target Disease Indication

§  Brain Metastases in Breast Cancer

§  Glioblastoma Multiforme

§  Hunter Syndrome

§  Hurler Syndrome

 

§  Leading Technology Platforms

§  G®-Technology

§  J-Brain Cargo® Technology

§  LRP-1 Technology

§  Trojan Horse Technology

 

§  Leading Drug Developers

§  2-BBB

§  Angiochem

§  ArmaGen

§  JCR Pharmaceuticals

 

§  Key Geographical Regions

§  North America

§  Europe

§  Asia-Pacific

 

 

The Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.”

 report features the following companies, which we identified to be key players in this domain:

§  Angiochem

§  ArmaGen

§  BioArctic

§  Cyclenium Pharma

§  Denali Therapeutics

§  ICB International

§  Iproteos

§  JCR Pharmaceuticals

§  Lauren Sciences

§  Medesis Pharma

§  Ossianix

§  Vect-Horus

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction
 

4. Market Landscape: Non-Invasive BBB Penetration
 

5. Market Landscape: BBB Penetrating Drugs
 

6. Company Profiles
 

7. Technology Competitiveness Analysis 
 

8. Non-Invasive BBB Penetration Technologies: Popular Approaches


9. Partnerships and Collaborations
 

10. Analysis of Recent Licensing Agreements
 

11. Funding and Investment Analysis
 

12. Patent Analysis
 

13. Drug Development Strategy Analysis
 

14. Market Potential of Key Neurological Disorders

 

15. Likely Partner Analysis

 

16. Market Forecast

 

17. Conclusion

 

18. Executive Insights

 

19. Appendix 1: Tabulated Data

 

20. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com 

0 Comments


Recommended Comments

There are no comments to display.

Guest
Add a comment...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
  • Create New...